# Savolitinib Plus Cetuximab and FOLFOX Chemotherapy for RAS/BRAF Wild-type Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct07683403/  
OnCo record `nct07683403` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in colorectal cancer, run by Fudan University, not yet recruiting.

## Summary

Savolitinib Plus Cetuximab and FOLFOX Chemotherapy for RAS/BRAF Wild-type Metastatic Colorectal Cancer is a phase 1/2, randomised interventional study registered as NCT07683403 by Fudan University, with a registry enrolment figure of 138 participants, started 2026-06-30 and due to reach its primary completion in 2028-06-30. Interventions recorded: Savolitinib plus cetuximab and FOLFOX chemotherapy; Cetuximab and FOLFOX chemotherapy. Conditions listed: Colorectal Cancer (CRC). Primary outcome: Objective response rate (ORR). Colorectal eligibility wording from the registry: "Histologically confirmed unresectable locally advanced or metastatic colorectal cancer;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07683403
- Phase: 1/2
- Setting: Savolitinib Plus Cetuximab and FOLFOX Chemotherapy Versus Cetuximab and FOLFOX Chemotherapy as First-line Treatment for RAS/BRAF Wild-type Metastatic Colorectal Cancer: a Prospective, Randomized, Controlled, Multicenter, Open-label Study
- Sponsor: Fudan University
- Enrolled: 138

## Sources

- ClinicalTrials.gov NCT07683403: https://clinicaltrials.gov/study/NCT07683403

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07683403.json